Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

UC San Diego researchers reveal key differences in PD-1 checkpoint receptors between rodents and humans. Rodent PD-1 is ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface of ...

GXP-1 is under clinical development by Egret Therapeutics and currently in Phase I for Transplant Rejection. According to GlobalData, Phase I drugs for Transplant Rejection have an 84% phase ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Renal Cell Carcinoma.

Integrin attachments to neighboring cells can break and reform as a cell moves (Figure 1 ... and death. Although it sounds like a bad thing, apoptosis — or the process of programmed cell ...

Westlake University in China and the California Institute of Technology have designed a protein-based system ... to stay alive or undergo programmed cell death. Cells naturally process multiple ...